The researchers designed an EGFR-targeting fusion protein consisting of recombinant gelonin (rGel) toxin and EGF, and PCI of rGel-EGF was applied to EGFR expressing tumor cells in vitro and in vivo. The gene discussed is EGF; the disease is neoplasm.